1. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000; 21: 168–199.
2. Melcescu E, Kemp EH, Majithia V, et al. Graves’ disease, hypoparathyroidism, systemic lupus erythematosus, alopecia, and angioedema: autoimmune polyglandular syndrome variant or coincidence? Int J Immunopathol Pharmacol. 2013; 26: 217–222.
3. Antonelli A, Fallahi P, Tolari S, et al. Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. Am J Med Sci. 2008; 336: 288–290.
4. Brent GA. Graves’ disease. N Engl J Med. 2008; 358: 2594–2605.
5. Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009; 360: 994–1001.
6. Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013; 98: 1443–1449.
7. Lesho E, Jones RE. Hypothyroid Graves’ disease. South Med J. 1997; 90: 1201–1203.
8. Khoo DH, Eng PH, Ho SC, et al. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000; 10: 1093–1100.
9. Marcocci C, Bartelena L, Bogazzi F, et al. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh). 1989; 120: 473–478.
10. Melcescu E, Horton WB, Pitman KT, et al. Euthyroid Graves’ orbitopathy and incidental papillary thyroid microcarcinoma. Hormones (Athens). 2013; 12: 298–304.
11. Fernando R, Atkins S, Raychaudhuri N, et al. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A. 2012; 109: 7427–7432.
12. Gillespie EF, Papagerogiou KI, Fernando R, et al. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012; 97: E70–E76.
13. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010; 362: 726–738.
14. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves’ ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 1995; 120: 511–517.
15. Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2007; 14: 398–409.
16. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism: the thyroid study group. N Engl J Med. 1992; 326: 1733–1738.
17. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998; 338: 73–78.
18. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves’ ophthalmopathy. Ann Intern Med. 1998; 129: 632–635.
19. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91: 3464–3470.
20. Tallstedt L, Lundell G, Blomgren H, et al. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994; 130: 494–497.
21. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996; 45: 477–481.
22. Prummel MF, Wiersinga WM, Mourits MP, et al. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh). 1989; 121: 185–189.
23. Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med. 1990; 150: 109–1101.
24. Bartalena L, Marcocci C, Pinchera A. Graves’ ophthalmopathy: a preventable disease? Eur J Endocrinol. 2002; 146: 457–461.
25. Dragan LR, Seiff SR, Lee DC. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2006; 22: 13–19.
26. Bahn RS, Heufelder AE. Mechanisms of disease: pathogenesis of Graves’ophthalmopathy. N Engl J Med. 1993; 329: 1468–1475.
27. Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000; 85: 1194–1199.
28. Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009; 94: 1803–1809.
29. Antonelli A, Ferrari SM, Frascerra S, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab. 2010; 95: E413–E420.
30. Leschik JJ, Diana T, Olivo PD, et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol. 2013; 139: 192–200.
31. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52: 267–271.
32. Schott M, Minich WB, Willenberg HS, et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves’ disease. Horm Metab Res. 2005; 37: 741–744.
33. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor gamma agonists. J Clin Endocrinol Metab. 2006; 91: 614–620.
34. Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001; 145: 107–118.
35. Müller-Forell W, Kahaly GJ. Neuroimaging of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26: 259–271.
36. Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves’ disease: computerized volume measurements of the orbital fat and muscle. Am J Neuroradiol. 1986; 7: 651–656.
37. Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbital involvement in Graves’ disease. N Engl J Med. 1974; 290: 1447–1450.
38. Erickson BA, Harris GJ, Lewandowski MF, et al. Echographic monitoring of response of extraocular muscles to irradiation in Graves’ ophthalmopathy. Int J Rad Oncol Biol Phys. 1995; 31: 651–660.
39. Batch JA, Lepre F. Early diagnosis of Graves’ optic neuropathy using visual evoked responses. Postgrad Med J. 1990; 66: 664–666.
40. Gasser P, Flammer J. Optic neuropathy of Graves’ disease. Ophthalmologica. 1986; 192: 22–27.
41. Ladenson PW, Stakes JW, Ridgway EC. Reversible alteration of the visual evoked potential in hypothyroidism. Am J Med. 1984; 77: 1010–1014.
42. Salvi M, Spaggiari E, Neri F, et al. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement. J Clin Endocrinol Metab. 1997; 82: 1027–1030.
43. Fatourechi V. Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab. 2012; 26: 553–565.
44. Mourits MP, Koorneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73: 639–644.
45. Gerding MN, Prummel MF, Kalmann R, et al. The use of colour slides in the assessment of changes in soft tissue involvement in Graves’ ophthalmopathy. J Endocrinol Invest. 1998; 21: 459–462.
46. Mourits MP, Prummel MF, Wiersinga WM, et al. Measuring eye movements in Graves’ ophthalmopathy. Ophthalmology. 1994; 101: 1341–1346.
47. Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997; 47: 9–14.
48. Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthal Plast Reconstr Surg. 2006; 22: 319–324.
49. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008; 18: 333–346.
50. Griepentrog GJ, Garrity JA. Update on the medical treatment of Graves’ ophthalmopathy. Int J Gen Med. 2009; 2: 263–269.
51. Bradley EL 3rd, DiGirolamo M. Remnant function after subtotal thyroidectomy for Graves’ disease. South Med J. 1975; 68: 1245–1258.
52. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011; 17: 456–520.
53. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves’ disease with a 5-year follow-up. Br J Surg. 2012; 99: 515–522.
54. Jarhult J, Rudberg C, Larsson E, et al. Graves’ disease with moderate-severe endocrine ophthalmopathy—long term results of a prospective randomized study of total or subtotal thyroid resection. Thyroid. 2005; 15: 1157–1165.
55. Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008; 158: 69–75.
56. Migliori ME, Gladstone GJ. Determination of the normal range of exophthalmometric values for black and white adults. Am J Ophthalmol. 1984; 98: 438–442.
57. Wu CH, Chang TC, Liao SL. Results and predictability of fat-removal orbital decompression for disfiguring Graves’ exophthalmos in an Asian patient population. Am J Ophthalmol. 2008; 145: 755–759.
58. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002; 12: 855–860.
59. Thornton J, Kelly SP, Harrison RA, et al. Cigarette smoking and thyroid eye disease: a systematic review. Eye (Lon). 2007; 21: 1135–1145.
60. Frueh BR. Why the NOSPECS classification of Graves’ eye disease should be abandoned, with suggestions for the characterization of this disease. Thyroid. 1992; 2: 85–88.
61. Gorman CA. The measurement of change in Graves’ ophthalmopathy. Thyroid. 1998; 8: 539–543.
62. Prummel MF, Suttorp-Schulten MS, Wiersinga WM, et al. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves’ ophthalmopathy. Ophthalmology. 1993; 100: 556–561.
63. Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid. 1998; 8: 429–432.
64. Utech CI, Khatibnia U, Winter PF, et al. T2 relaxation time for the assessment of retrobulbar inflammation in Graves’ ophthalmopathy. Thyroid. 1995; 5: 185–193.
65. Postema PTE, Krenning EP, Wijngaarde R, et al. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab. 1994; 79: 1845–1851.
66. Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002; 109: 1183–1187.
67. Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011; 364: 1920–1931.
68. Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26: 325–337.
69. Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013; 78: 155–164.
70. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009; 94: 2708–2716.
71. Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96: 320–332.
72. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001; 86: 3562–3567.
73. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single-blind trial of intravenous v oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005; 90: 5234–5240.
74. Marino M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004; 14: 403–406.
75. Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2007; 17: 357–362.
76. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010; 95: 1333–1337.
77. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves’ orbitopathy: randomized placebo-controlled study. Lancet. 2000; 355: 1505–1509.
78. Kahaly GJ, Rosler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000; 85: 102–108.
79. Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2003; 88: 3561–3566.
80. Wakelkamp IM, Tan H, Saeed P, et al. Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004; 111: 1557–1562.
81. Robertson DM, Buettner H, Gorman CA, et al. Retinal microvascular abnormalities in patients treated with external radiation for Graves’ ophthalmopathy. Arch Ophthalmol. 2003; 121: 652–657.
82. Cockerham KP, Kennerdell JS. Does radiotherapy have a role in the management of thyroid orbitopathy? Br J Ophthalmol. 2002; 86: 102–104.
83. Ng CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J. 2005; 11: 322–330.
84. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves’ ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008; 115: 398–409.
85. Borumandi F, Hammer B, Kamer L, et al. How predictable is exophthalmos reduction in Graves’ orbitopathy? A review of the literature. Br J Ophthalmol. 2011; 95: 1625–1630.
86. Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 2005; 63: 323–328.
87. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005; 90: 841–848.
88. Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990; 122: 8–12.
89. Kahaly G, Lieb W, Muller-Forell W, et al. Ciamexone in endocrine orbitopathy. A randomized, double-blind, placebo-controlled study. Acta Endocrinol (Copenh). 1990; 122: 13–21.
90. Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves’ ophthalmopathy. Acta Endocrinol (Copenh). 1992; 126: 13–23.
91. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007; 156: 33–40.
92. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond). 2005; 19: 1286–1289.
93. Madaschi S, Rossini A, Formenti I, et al. Treatment of thyroid-associated orbitopathy with rituximab—a novel therapy for an old disease: case report and literature review. Endocr Pract. 2010; 16: 677–685.
94. Salvi M, Vannucchi G, Curro N, et al. Small dose of rituximab for Graves’ orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012; 130: 122–124.
95. Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986; 16: 415–422.
96. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989; 321: 1353–1359.
97. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993; 328: 106–113.